Cary P. Gross, MD

Evidentiary standards for new or supplementary cancer therapeutic indication approvals by the FDA are consistent with off-label indication inclusions on Medicare-referenced compendia.

Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.